PPARγ agonists have shown beneficial effects in anti-lung cancer, including disruption of tumor metabolic homeostasis, promotion of cell apoptosis, induction of cell cycle arrest, as well as inhibition of cell invasion and angiogenesis. Here, PPARG is linked to lung cancer.